



Docket No. DIV-1460-21US (112766-199)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Short et al. Confirmation No. 4125
U.S. Serial No.: 10/029,221
Filing Date: December 21, 2002
Title: EXONUCLEASE-MEDIATED NUCLEIC ACID REASSEMBLY IN
DIRECTED EVOLUTIONS

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to BOX MISSING PARTS Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: Sept. 20, 2002

By: Nancy E. Gilmore
Nancy E. Gilmore

BOX MISSING PARTS
Commissioner For Patents
Washington, D.C. 20231

**COMMUNICATION IN REPLY TO AUGUST 26, 2002 NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Dear Commissioner:

This Communication is submitted in reply to the Notice mailed August 26, 2002 in connection with the above-identified application. A reply is due October 26, 2002. Therefore, this Communication is being timely filed.

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed by the United States Patent and Trademark Office on August 26, 2002, applicant submits the following documents for filing in the above-referenced patent application:

Applicants: Jay M. Short et al.

U.S. Serial No.: 10/029,221

Filed: December 21, 2002

Page 2

1. A copy of the Notice Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on August 26, 2002;
2. Statement Under 37 C.F.R. §1.821(f)
3. A computer readable form (CRF) (diskette) containing the Sequence Listing submitted on July 8, 2002 in electronic form; and
4. Return Postcard.

No fees are believed to be due in connection with this letter. However, please charge any additional costs or credit any overpayment to maintain the pendency of this application to our Deposit Account No. 08-0219.

If there are any questions, please call the undersigned at the telephone number indicated below.

Date: 9/20/02

Respectfully submitted,

Jane M. Love

Jane M. Love, Ph.D.

Registration No. 42,812

Attorney for Applicants

Hale and Dorr LLP
300 Park Avenue
New York, NY 10022
Tel. (212) 937-7233
Fax. (212) 937-7300



UNITED STATES PATENT AND TRADEMARK OFFICE


 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/029,221	12/21/2001	Jay M. Short	112766.199 (DIV-1460-21US)

 Jane M. Love, Ph.D.
 Hale and Dorr LLP
 300 Park Avenue
 New York, NY 10022

CONFIRMATION NO. 4125

FORMALITIES LETTER



OC000000008683475

Date Mailed: 08/26/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

 Customer Service Center
 Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE